Research and publish the best content.
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Already have an account: Login
Immunopathology & Immunotherapy
10.4K views |
+0 today
Latest advances in immunopathology diagnosis and treatment
Curated by
Alfredo Corell
 Your new post is loading...
Your new post is loading...
|
Scoop.it!
Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study. Sune F Nielsen, Stig E Bojesen, Peter Schnohr, Børge G Nordestgaard. BMJ 2012; 345 doi: 10.1136/bmj.e5244 (Published 6 September 2012)Cite this as: BMJ 2012;345:e5244 Conclusion Individuals in the general population with elevated rheumatoid factor have up to 26-fold greater long term risk of rheumatoid arthritis, and up to 32% 10 year absolute risk of rheumatoid arthritis. These novel findings may lead to revision of guidelines for early referral to a rheumatologist and early arthritis clinics based on rheumatoid factor testing. 
|
Theofilopoulos and Baccala are confident that SLC15A4 is a potential target for a new SLE therapy. A drug that would target SLC15A4 could potentially suppress only the immune cells directly responsible for SLE, without affecting the rest of the immune system. The research team is currently trying to develop a new pharmacological compound capable of inhibiting the production of type 1 interferon. This inhibition would be possible if the expression of the SLC15A4 gene could be blocked.
Read more: http://www.doctortipster.com/12745-new-drug-target-for-lupus-revealed-by-researchers.html#ixzz2KUecwyj0